Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

• Main Authors: Jun Lu (Author), Wei Xu (Author), Jie Qian (Author), Shuyuan Wang (Author), Bo Zhang (Author), Lele Zhang (Author), Rong Qiao (Author), Minjuan Hu (Author), Yiming Zhao (Author), Xiaodong Zhao (Author), Baohui Han (Author)
• Format: Book
• Published: BMC, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Anlotinib has been demonstrated its anti-tumor efficacy on non-small cell lung cancer (NSCLC) in clinical trials at 3rd line. However, anlotinib resistance occurs during its administration, and the underlying mechanism is still unclear. Methods Anlotinib resistant lung cancer cel...